stockrowScienture Holdings, Inc.
SCNX Healthcare Pharmaceutical Retailers
Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024.
- Revenue
- +3,235.9%
- EPS
- +85.4%
- Free cash flow
- −54.0%
- Total debt
- +831.4%
Quarter to June 2026, against a year earlier
Follow SCNX
Alert me
Scienture Holdings, Inc. (SCNX) EV/Sales
As of 6 November 2026, Scienture Holdings, Inc. (SCNX) trades at a EV/Sales of 8.4×. Over the past ten years it has ranged from −1.8× (March 2026) to 244× (August 2025); the current reading is higher than 67% of that period. That is above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.8× | (92.06%) |
| FY2024 | 85.1× | 2,580.96% |
| FY2023 | 3.2× | 1,447.59% |
| FY2022 | 0.2× | (88.30%) |
| FY2021 | 1.8× | (15.65%) |
| FY2020 | 2.1× | (57.73%) |
| FY2019 | 4.9× | 101.00% |
| FY2018 | 2.4× | (51.12%) |
| FY2017 | 5.0× | (14.68%) |
| FY2016 | 5.9× | (50.35%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 19.2× | (7.68%) |
| Mar 2026 | 20.8× | 208.08% |
| Dec 2025 | 6.8× | (72.83%) |
| Sep 2025 | 24.9× | (72.17%) |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDGT Ridgetech Inc. compare | 0.0× |
| POM Pomdoctor Limited - Sponsored ADR compare | n/m |
| PETS PetMed Express, Inc. compare | 0.1× |
| HITI High Tide Inc. compare | 0.5× |
| SCNX Scienture Holdings, Inc. | 8.4× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)